- $1.39bn
- $1.48bn
- $53.04m
AnaptysBio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular Psoriasis
Brief: Anaptys To Receive $50 Mln In Capped Non-Recourse Monetization From Amended Agreement With Sagard In Exchange For Additional Jemperli Royalties
Brief: AnaptysBio Q1 Net Income USD -43.936 Million
AnaptysBio Inc expected to post a loss of $1.57 a share - Earnings Preview
AnaptysBio Inc reports results for the quarter ended in December - Earnings Summary
Brief: AnaptysBio Q4 Net Income USD -42.211 Million
AnaptysBio Inc expected to post a loss of $1.63 a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Booking Holdings, Eli Lilly, Markel Group
Brief: AnaptysBio Q3 net income USD -37.308 million
U.S. STOCKS ON THE MOVE-Illumina, AnaptysBio, Royal Caribbean Group
Anaptys soars as skin disease treatment succeeds in late-stage study
AnaptysBio's skin disease drug meets main goal in late-stage study (updated)
Brief: Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results Of Imsidolimab (Il-36R)
AnaptysBio's skin disease drug meets main goal in late-stage study
Brief: Anaptysbio Announces Appointment Of John Orwin As Chairman Of The Board Of Directors
AnaptysBio Inc reports results for the quarter ended in June - Earnings Summary
AnaptysBio Inc expected to post a loss of $1.70 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Anaptysbio, Booking Holdings, Ulta Beauty